SMS Lifesciences India Ltd. (IN:HALEOSLABS)

:HALEOSLABS

HALEOSLABS

SMS Lifesciences India Ltd.

RESEARCH TOOLSreports

Want to see IN:HALEOSLABS full AI Analyst Report?

SMS Lifesciences India Ltd. (HALEOSLABS) Price & Analysis

1 Followers

HALEOSLABS Stock Chart & Stats

₹1105.00

₹4.55(0.36%)

At close: Jan 08 4:00 PM EST

₹1105.00

₹4.55(0.36%)

Day’s Range― - ―

52-Week Range₹1,050.05 - ₹1,778.35

Previous CloseN/A

VolumeN/A

Average Volume (3M)154.00

Market Cap

₹4.10B

Enterprise Value₹5.47B

Total Cash (Recent Filing)₹11.92M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)23.0

Beta0.98

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)48.10

Shares Outstanding3,023,287

10 Day Avg. Volume53

30 Day Avg. Volume154

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)2.00

Price to Sales (P/S)1.17

P/FCF Ratio21.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Revenue GrowthSustained ~62.6% revenue growth shows durable demand for SMS Lifesciences' APIs across domestic and export channels. Higher top-line traction strengthens scale economics, supports reinvestment in capacity, and increases resilience to single-product shocks over the medium term.

Strong Margin ProfileReported strong EBIT/EBITDA margins and improving net profit margin signal structural profitability and operational efficiency in small-molecule API production. Consistent margins support internal cash generation and the ability to absorb input cost swings while funding growth without persistent external financing.

Balanced Leverage & Solid ROEA reasonable debt-to-equity level alongside solid return on equity indicates efficient capital use and manageable leverage. This balance supports funding incremental capacity or customer qualification investments while keeping default and refinancing risk contained in normal cycles.

Bears Say

Cash Flow VolatilityDespite recent free cash flow improvement, documented historical inconsistencies imply operational cash conversion can fluctuate. Variable cash flows can constrain scheduled capex, delay customer qualification projects, and limit steady deleveraging or dividend policies over the medium term.

Gross Margin VolatilityReported volatility in gross profit margin points to exposure to raw-material pricing, yield variability or production inefficiencies. For an API manufacturer, persistent gross-margin swings can erode sustainable profitability and require ongoing investments in process control and procurement discipline.

Moderate Reliance On LiabilitiesA moderate reliance on liabilities reduces balance-sheet flexibility in economic stress and can raise funding costs if market conditions tighten. For capital-intensive API manufacturing, this reliance may limit competitive agility for new molecule qualification or capacity expansion during downturns.

SMS Lifesciences India Ltd. News

Haleos Labs Publishes Postal Ballot Notice, Opens SEBI-Compliant Special Window

SMS Lifesciences India Ltd. ( ($IN:HALEOSLABS) ) just unveiled an announcement. Haleos Labs Limited has notified the stock...

3M ago

HALEOSLABS FAQ

What was SMS Lifesciences India Ltd.’s price range in the past 12 months?

SMS Lifesciences India Ltd. lowest stock price was ₹1050.05 and its highest was ₹1778.35 in the past 12 months.

What is SMS Lifesciences India Ltd.’s market cap?

SMS Lifesciences India Ltd.’s market cap is ₹4.10B.

When is SMS Lifesciences India Ltd.’s upcoming earnings report date?

SMS Lifesciences India Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 52 days.

How were SMS Lifesciences India Ltd.’s earnings last quarter?

SMS Lifesciences India Ltd. released its earnings results on May 29, 2026. The company reported ₹1.44 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.44.

Is SMS Lifesciences India Ltd. overvalued?

According to Wall Street analysts SMS Lifesciences India Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SMS Lifesciences India Ltd. pay dividends?

SMS Lifesciences India Ltd. pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.12%. See more information on SMS Lifesciences India Ltd. dividends here

What is SMS Lifesciences India Ltd.’s EPS estimate?

SMS Lifesciences India Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SMS Lifesciences India Ltd. have?

SMS Lifesciences India Ltd. has 3,023,287 shares outstanding.

What happened to SMS Lifesciences India Ltd.’s price movement after its last earnings report?

SMS Lifesciences India Ltd. reported an EPS of ₹1.44 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.678%.

Which hedge fund is a major shareholder of SMS Lifesciences India Ltd.?

Currently, no hedge funds are holding shares in IN:HALEOSLABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SMS Lifesciences India Ltd.

Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.